Gilead is testing an inhaled version of remdesivir. The antiviral drug is currently given intravenously, but a new trial is testing a version of the drug given through a nebulizer. The inhaled version will begin phase 1 trials in August. (The New York Times)

Akili Interactive Labs’ newly approved video game to treat ADHD could shape future digital therapeutics. The company is navigating how to persuade doctors to prescribe a game and how to convince insurers to pay for the treatment. (STAT)

Register to attend MM&M Convene Crisis Control webcast on Thursday. MM&M will bring together communications leaders to discuss how the COVID-19 pandemic fundamentally changed healthcare communications, from social media to HCP outreach. (MM&M)

The National Institutes of Health has ended two trials of hydroxychloroquine in COVID-19 patients. The oversight board for the trials determined that the antimalarial drug was not preventing death or invasive treatment like mechanical ventilation. (BioPharma Dive)

Gilead expects to have more than 2 million doses of remdesivir by the end of 2020. The company previously expected to have 1 million courses of treatment for the antiviral drug. (Reuters)